1
|
Miller EW, Roberts B, Keeton K, Monnot A, Tarpey T, Zoghby N, Segrave A, Pierce JS. Evaluation of asbestos exposure resulting from simulated application of spiked talcum powders. Inhal Toxicol 2022; 34:380-398. [PMID: 36227690 DOI: 10.1080/08958378.2022.2132324] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
This study characterizes airborne asbestos exposures resulting from the adult application of cosmetic talc body powders spiked with known concentrations of tremolite. Raw talc ores were spiked with 0.005% and 0.1% asbestiform or non-asbestiform tremolite. Personal samples were collected during 16 simulated events, including puff and shaker application and associated clean-up activities. Airborne fiber levels (PCM) were not significantly different for simulations involving talc spiked with asbestiform and non-asbestiform tremolite (p = 0.6104). For application and clean-up of talc spiked with 0.005% asbestiform tremolite, 2 of 24 (8.3%) samples were above the LOD for TEM (0.003 f/cc). For application of talc spiked with 0.1% asbestiform tremolite, 21 of 24 (87.5%) were above the LOD for TEM. The corresponding mean PCME asbestos concentrations were 0.016 f/cc for puff and shaker for samples collected in the first 15 min, 0.002 f/cc for puff and 0.004 f/cc for shaker in the second 15 min, and 0.005 f/cc for puff and 0.013 f/cc for shaker for the full 30 min. Mean PCME concentrations for samples collected during clean-up following application of talc spiked with 0.1% asbestiform tremolite were 0.003 f/cc for samples collected in the first 15 min following puff application, 0.005 f/cc for samples collected in the second 15 min following shaker application, and 0 f/cc for the remaining clean-up samples. Using the EPA's exposure factors, we determined the range of cumulative asbestiform fiber exposures that would result from product use, assuming asbestiform tremolite was present at 0.1%.
Collapse
Affiliation(s)
- Eric W Miller
- Cardno ChemRisk, Chicago, IL, USA.,Benchmark Risk Group, Grand Rapids, MI
| | - Benjamin Roberts
- Cardno ChemRisk, Chicago, IL, USA.,Benchmark Risk Group, Grand Rapids, MI
| | | | | | | | | | - Alan Segrave
- Segrave Technical Consulting, LLC, Marietta, GA, USA
| | - Jennifer S Pierce
- Cardno ChemRisk, Chicago, IL, USA.,Benchmark Risk Group, Chicago, IL
| |
Collapse
|
2
|
Abstract
OBJECTIVE Mycotic aortic aneurysm is a rare and life-threatening pathology. The first case of mycotic aneurysm induced by immunotherapy with bacille Calmette-Guérin for malignancy was published in 1988. The main objective of this review is to characterize this rare pathology. MATERIALS AND METHODS Since then, 60 cases of arterial aneurysm following intra vesical BCG instillation have been described in the literature. All cases have been included, and characteristics have been collected retrospectively, with simple statistical analyses of the cases. RESULTS We present a brief review from 1988 to 2022 enhancing the contemporary understanding of this arterial infection. Mycotic aneurysm secondary to BCG instillation has a poor prognosis, up to 50% complication and 15% mortality at 1 month, whether managed by open repair or endovascular means. CONCLUSION BCG mycotic aneurysm is an extremely serious condition, the diagnosis of which must be considered at an early stage in order to adapt diagnostic and therapeutic strategies.
Collapse
Affiliation(s)
- M Palmier
- Department of vascular surgery, Rouen university hospital, 1, rue de Germont, 76031 Rouen cedex, France.
| | - A Monnot
- Department of vascular surgery, Rouen university hospital, 1, rue de Germont, 76031 Rouen cedex, France
| | - T Tenière
- Department of vascular surgery, Rouen university hospital, 1, rue de Germont, 76031 Rouen cedex, France
| | - Q Cohen
- Department of vascular surgery, Rouen university hospital, 1, rue de Germont, 76031 Rouen cedex, France
| | - D Plissonnier
- Department of vascular surgery, Rouen university hospital, 1, rue de Germont, 76031 Rouen cedex, France
| |
Collapse
|
3
|
Eichenbaum G, Wilsey JT, Fessel G, Qiu QQ, Perkins L, Hasgall P, Monnot A, More SL, Egnot N, Sague J, Marcello S, Connor K, Scutti J, Christian WV, Coplan PM, Wright J, Hastings B, Katz LB, Vreeke M, Calistri-Yeh M, Faiola B, Purushothaman B, Nevelos J, Bashiri M, Christensen JB, Kovochich M, Unice K. An integrated benefit-risk assessment of cobalt-containing alloys used in medical devices: Implications for regulatory requirements in the European Union. Regul Toxicol Pharmacol 2021; 125:105004. [PMID: 34256083 DOI: 10.1016/j.yrtph.2021.105004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 05/27/2021] [Accepted: 07/09/2021] [Indexed: 11/15/2022]
Abstract
In 2017, the European Union (EU) Committee for Risk Assessment (RAC) recommended the classification of metallic cobalt (Co) as Category 1B with respect to its carcinogenic and reproductive hazard potential and Category 2 for mutagenicity but did not evaluate the relevance of these classifications for patients exposed to Co-containing alloys (CoCA) used in medical devices. CoCA are inherently different materials from Co metal from a toxicological perspective and thus require a separate assessment. CoCA are biocompatible materials with a unique combination of properties including strength, durability, and a long history of safe use that make them uniquely suited for use in a wide-range of medical devices. Assessments were performed on relevant preclinical and clinical carcinogenicity and reproductive toxicity data for Co and CoCA to meet the requirements under the EU Medical Device Regulation triggered by the ECHA re-classification (adopted in October 2019 under the 14th Adaptation to Technical Progress to CLP) and to address their relevance to patient safety. The objective of this review is to present an integrated overview of these assessments, a benefit-risk assessment and an examination of potential alternative materials. The data support the conclusion that the exposure to CoCA in medical devices via clinically relevant routes does not represent a hazard for carcinogenicity or reproductive toxicity. Additionally, the risk for the adverse effects that are known to occur with elevated Co concentrations (e.g., cardiomyopathy) are very low for CoCA implant devices (infrequent reports often reflecting a unique catastrophic failure event out of millions of patients) and negligible for CoCA non-implant devices (not measurable/no case reports). In conclusion, the favorable benefit-risk profile also in relation to possible alternatives presented herein strongly support continued use of CoCA in medical devices.
Collapse
Affiliation(s)
- Gary Eichenbaum
- Johnson & Johnson, 410 George St, New Brunswick, NJ, 08901, USA
| | - Jared T Wilsey
- Smith & Nephew, 1450 E Brooks Rd, Memphis, TN, 38116, USA
| | - Gion Fessel
- Smith & Nephew, Oberneuhofstasse 10D, 6340, Baar, Switzerland
| | - Qing-Qing Qiu
- Stryker, 2825 Airview Boulevard, Kalamazoo, MI, 49002, USA
| | - Laura Perkins
- Abbott Vascular, 3200 Lakeside Dr, Santa Clara, CA, 95054, USA
| | | | - Andrew Monnot
- Cardno ChemRisk, 235 Pine Street Suite 2300, San Francisco, CA, 94104, USA
| | - Sharlee L More
- Cardno ChemRisk, 6720 S Macadam Ave Suite 150, Portland, OR, 97219, USA
| | - Natalie Egnot
- Cardno ChemRisk, 20 Stanwix Street Suite 505, Pittsburgh, PA, 15222, USA
| | - Jorge Sague
- Stryker, 2825 Airview Boulevard, Kalamazoo, MI, 49002, USA
| | | | - Kevin Connor
- Boston Scientific, 100 Boston Scientific Way, Marlborough, MA, 01752, USA
| | - James Scutti
- Boston Scientific, 100 Boston Scientific Way, Marlborough, MA, 01752, USA
| | | | - Paul M Coplan
- Johnson & Johnson, 410 George St, New Brunswick, NJ, 08901, USA; University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA
| | - John Wright
- Johnson & Johnson, 410 George St, New Brunswick, NJ, 08901, USA
| | - Bob Hastings
- Johnson & Johnson, 410 George St, New Brunswick, NJ, 08901, USA
| | - Laurence B Katz
- LifeScan Global Corporation, 20 Valley Stream Parkway, Malvern, PA, 19355, USA
| | - Mark Vreeke
- Edwards Lifesciences, One Edwards Way, Irvine, CA, 92614, USA
| | | | - Brenda Faiola
- Becton Dickinson, 1 Becton Drive, Franklin Lakes, NJ, 07417, USA; Rho, Inc., 2635 E NC Hwy 54, Durham, NC, 27713, USA
| | | | - Jim Nevelos
- Stryker, 2825 Airview Boulevard, Kalamazoo, MI, 49002, USA
| | - Mehran Bashiri
- Stryker Neurovascular, 47900 Bayside Parkway, Fremont, CA, 94538, USA
| | | | - Michael Kovochich
- Cardno ChemRisk, 30 North LaSalle St Suite 3910, Chicago, Illinois, 60602-2590, USA
| | - Kenneth Unice
- Cardno ChemRisk, 20 Stanwix Street Suite 505, Pittsburgh, PA, 15222, USA.
| |
Collapse
|
4
|
Garnick L, Massarsky A, Mushnick A, Hamaji C, Scott P, Monnot A. An evaluation of health-based federal and state PFOA drinking water guidelines in the United States. Sci Total Environ 2021; 761:144107. [PMID: 33360549 DOI: 10.1016/j.scitotenv.2020.144107] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Revised: 11/19/2020] [Accepted: 11/22/2020] [Indexed: 06/12/2023]
Abstract
Perfluorooctanoic acid (PFOA) is a synthetic, perfluorinated organic acid previously used in fluoropolymer production in the United States. PFOA has been a recent focal point for regulation because of its ubiquitous presence in drinking water throughout the United States. In 2016, the United States Environmental Protection Agency (US EPA) issued a lifetime drinking water Health Advisory (HA) for PFOA of 0.07 μg/L; several states have also implemented their own drinking water guidelines for PFOA. The current study aimed to evaluate the basis and derivation of state and federal guidelines for PFOA in drinking water, with particular emphasis on the exposure parameters utilized. Twelve distinct PFOA drinking water standards were identified ranging from 0.0051 to 2 μg/L. The US EPA HA assumptions were evaluated using a Monte Carlo analysis that included distributions for drinking water intake (DWI) rate and the relative source contribution (RSC). We determined that US EPA's HA of 0.07 μg/L is protective of 99% of the population of lactating women. We also demonstrated that the health-based guidelines were highly variable across states and that the actual RSC of PFOA from drinking water is likely greater than 20%, based on studies of actual PFOA exposures from dust, water, and food. A sensitivity analysis was performed using the same equations as the US EPA, while substituting the RSC and DWI variables; resulting in HAs ranging from 0.074 to 0.346 μg/L. We also evaluated the contribution of PFOA in drinking water to the systemic PFOA body burden of the general population using an available biokinetic model. We conclude that more rigorous efforts are warranted to establish consistent health-based drinking water guidelines for PFOA, given that drinking water is a primary source of human exposure to PFOA in the United States.
Collapse
Affiliation(s)
- Lindsey Garnick
- Cardno ChemRisk, San Francisco, CA 94104, United States of America
| | - Andrey Massarsky
- Cardno ChemRisk, Aliso Viejo, CA 92656, United States of America
| | - Adam Mushnick
- Cardno ChemRisk, San Francisco, CA 94104, United States of America; Duke University Nicholas School of the Environment, Durham, NC 27705, United States of America
| | - Claire Hamaji
- Cardno ChemRisk, San Francisco, CA 94104, United States of America
| | - Paul Scott
- Cardno ChemRisk, Pittsburgh, PA 15222, United States of America
| | - Andrew Monnot
- Cardno ChemRisk, San Francisco, CA 94104, United States of America.
| |
Collapse
|
5
|
Zisook RE, Monnot A, Parker J, Gaffney S, Dotson S, Unice K. Assessing and managing the risks of COVID-19 in the workplace: Applying industrial hygiene (IH)/occupational and environmental health and safety (OEHS) frameworks. Toxicol Ind Health 2020; 36:607-618. [PMID: 33085585 PMCID: PMC7578844 DOI: 10.1177/0748233720967522] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 09/16/2020] [Accepted: 09/18/2020] [Indexed: 12/02/2022]
Abstract
As businesses attempt to reopen to varying degrees amid the current coronavirus disease (COVID-19) pandemic, industrial hygiene (IH) and occupational and environmental health and safety (OEHS) professionals have been challenged with assessing and managing the risks of COVID-19 in the workplace. In general, the available IH/OEHS tools were designed to control hazards originating in the workplace; however, attempts to tailor them specifically to the control of infectious disease outbreaks have been limited. This analysis evaluated the IH decision-making framework (Anticipate, Recognize, Evaluate, Control, and Confirm ("ARECC")) as it relates to biological hazards, in general, and to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), specifically. Available IH/OEHS risk assessment and risk management tools (e.g. control banding and the hierarchy of controls) are important components of the ARECC framework. These conceptual models, however, were primarily developed for controlling chemical hazards and must be adapted to the unique characteristics of highly infectious and virulent pathogens, such as SARS-CoV-2. This assessment provides an overview of the key considerations for developing occupational infection control plans, selecting the best available controls, and applying other emerging tools (e.g. quantitative microbial risk assessment), with the ultimate goal of facilitating risk management decisions during the current global pandemic.
Collapse
|
6
|
Rovacchi R, Alexandre K, Fiaux E, Monnot A, Boutin A, Benadiba L, Frebourg N, Selim J, Plissonnier D, Dusseaux M. Infections de prothèse vasculaire : efficacité d’une prise en charge pluridisciplinaire. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Simon D, Cailleux-Talbot N, Armengol G, Benhamou Y, Lévesque H, Monnot A, Miranda S. [A neck mass]. Rev Med Interne 2019; 41:348-349. [PMID: 31662231 DOI: 10.1016/j.revmed.2019.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Revised: 09/19/2019] [Accepted: 09/26/2019] [Indexed: 11/18/2022]
Affiliation(s)
- D Simon
- UNIROUEN, service de médecine interne, Normandie université, 76000 Rouen, France.
| | - N Cailleux-Talbot
- UNIROUEN, service de médecine interne, Normandie université, 76000 Rouen, France
| | - G Armengol
- UNIROUEN, service de médecine interne, Normandie université, 76000 Rouen, France
| | - Y Benhamou
- UNIROUEN, service de médecine interne, Normandie université, 76000 Rouen, France; UNIROUEN, U1096, service de médecine interne, Normandie université, 76000 Rouen, France
| | - H Lévesque
- UNIROUEN, service de médecine interne, Normandie université, 76000 Rouen, France; UNIROUEN, U1096, service de médecine interne, Normandie université, 76000 Rouen, France
| | - A Monnot
- UNIROUEN, service de chirurgie vasculaire, Normandie université, 76000 Rouen, France
| | - S Miranda
- UNIROUEN, service de médecine interne, Normandie université, 76000 Rouen, France; UNIROUEN, U1096, service de médecine interne, Normandie université, 76000 Rouen, France
| |
Collapse
|
8
|
Monnot A, Pochulu B, Godier S, Plissonnier D. A case of a 15-year evolution of a coral reef aortic lesion. J Med Vasc 2019; 44:205-208. [PMID: 31029275 DOI: 10.1016/j.jdmv.2019.02.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/21/2018] [Accepted: 02/08/2019] [Indexed: 11/19/2022]
Abstract
We are reporting here the 15-year history of a patient affected by a chronic and evolutive coral reef aorta successfully treated by repeated revascularization.
Collapse
Affiliation(s)
- A Monnot
- Service de chirurgie vasculaire, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France
| | - B Pochulu
- Service de chirurgie vasculaire, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France
| | - S Godier
- Service d'anesthésie réanimation, CHU Rouen, 1, rue de Germont, 76031 Rouen cedex, France
| | - D Plissonnier
- Service de chirurgie vasculaire, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France.
| |
Collapse
|
9
|
Fung ES, Monnot A, Kovochich M, Unice KM, Tvermoes BE, Galbraith D, Finley BL, Paustenbach DJ. Characteristics of Cobalt-Related Cardiomyopathy in Metal Hip Implant Patients: An Evaluation of 15 Published Reports. Cardiovasc Toxicol 2017; 18:206-220. [PMID: 29188590 DOI: 10.1007/s12012-017-9433-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Over 300,000 hip replacements occurred in the USA in 2010, and the frequency is likely increasing annually. Blood Cobalt (Co) concentrations in patients with well-functioning cobalt-chromium (Co-Cr) hip implants are usually elevated above background concentrations relative to the general population. Excessive Co exposure, in rare cases, can result in cardiomyopathy. The purpose of this review was to identify cases of cardiomyopathy in metal-containing hip implant patients and to evaluate the possible cause of each patient's cardiomyopathy. We evaluated 15 cases published between 2009 and 2016, and, based on a review of the preexisting risk factors, blood Co concentrations, and histopathological information published for each patient, they were stratified into one of four categories regarding the association between Co exposure and the development of cardiomyopathy: (1) Co was causal (five cases); (2) Co was contributory (two cases); (3) Co was possibly contributory (six cases); and (4) Co was non-causal (two cases). In all 15 cases, blood Co concentrations (14-6521 μg/L) were elevated beyond levels associated with the majority of metal-containing implant patients (0.1-10 μg/L), and, in many cases, there was evidence of a malfunctioning implant. The data indicate that individuals with well-functioning implants, even those with preexisting risk factors, are at no risk of developing cardiac effects. We conclude that blood Co measurements are informative, but should be interpreted with caution, and in context of other factors evaluated in this analysis. The mere presence of elevated Co is not sufficient to indicate causation for a patient's cardiomyopathy.
Collapse
Affiliation(s)
- Ernest S Fung
- Cardno ChemRisk, 65 Enterprise, Suite 150, Aliso Viejo, CA, 92656, USA
| | - Andrew Monnot
- Cardno ChemRisk, 101 2nd St. Suite 700, San Francisco, CA, 94105, USA
| | - Michael Kovochich
- Cardno ChemRisk, 65 Enterprise, Suite 150, Aliso Viejo, CA, 92656, USA.
| | - Kenneth M Unice
- Cardno ChemRisk, 20 Stanwix St. Suite 505, Pittsburgh, PA, 15222, USA
| | - Brooke E Tvermoes
- Cardno ChemRisk, 4940 Pearl East Circle Suite 100, Boulder, CO, 80301, USA.,IBM, Boulder, CO, USA
| | - David Galbraith
- Cardno ChemRisk, 101 2nd St. Suite 700, San Francisco, CA, 94105, USA
| | - Brent L Finley
- Cardno ChemRisk, 231 Front St. Suite 212, Brooklyn, NY, 11201, USA
| | | |
Collapse
|
10
|
Perez AL, Nembhard M, Monnot A, Bator D, Madonick E, Gaffney SH. Supplementary dataset for child and adult exposure and health risk evaluation following the use of metal- and metalloid-containing costume cosmetics sold in the United States. Data Brief 2017; 13:129-131. [PMID: 28603757 PMCID: PMC5451178 DOI: 10.1016/j.dib.2017.04.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2016] [Revised: 04/10/2017] [Accepted: 04/21/2017] [Indexed: 11/26/2022] Open
Abstract
The data presented in this article are related to the research article entitled "Child and adult exposure and health risk evaluation following the use of metal- and metalloid-containing costume cosmetics sold in the United States" [1]. This article describes the concentration of metals and metalloids contained in various cosmetic products such as body paint, lipstick and eye shadow, the relative percent deviation of two analyses performed on the products and the physico-chemico properties of the metals and metalloids used in the SkinPerm model presented in the aforementioned article.
Collapse
Affiliation(s)
- Angela L Perez
- Cardno ChemRisk, LLC, 101 2nd Street, Suite 700, San Francisco, CA 94105, United States
| | - Melanie Nembhard
- Cardno ChemRisk, LLC, 101 2nd Street, Suite 700, San Francisco, CA 94105, United States
| | - Andrew Monnot
- Cardno ChemRisk, LLC, 101 2nd Street, Suite 700, San Francisco, CA 94105, United States
| | - Daniel Bator
- Dept. of Environmental Health Sciences, University of Michigan School of Public Health, 1415 Washington Heights, Ann Arbor, MI 48109-2029, United States
| | | | - Shannon H Gaffney
- Cardno ChemRisk, LLC, 101 2nd Street, Suite 700, San Francisco, CA 94105, United States
| |
Collapse
|
11
|
Damon C, Luck M, Toullec L, Etienne I, Buchler M, Hurault de Ligny B, Choukroun G, Thierry A, Vigneau C, Moulin B, Heng AE, Subra JF, Legendre C, Monnot A, Yartseva A, Bateson M, Laurent-Puig P, Anglicheau D, Beaune P, Loriot MA, Thervet E, Pallet N. Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. Am J Transplant 2017; 17:1008-1019. [PMID: 27597269 DOI: 10.1111/ajt.14040] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Revised: 08/24/2016] [Accepted: 08/26/2016] [Indexed: 01/25/2023]
Abstract
Any biochemical reaction underlying drug metabolism depends on individual gene-drug interactions and on groups of genes interacting together. Based on a high-throughput genetic approach, we sought to identify a set of covariant single-nucleotide polymorphisms predictive of interindividual tacrolimus (Tac) dose requirement variability. Tac blood concentrations (Tac C0 ) of 229 kidney transplant recipients were repeatedly monitored after transplantation over 3 mo. Given the high dimension of the genomic data in comparison to the low number of observations and the high multicolinearity among the variables (gene variants), we developed an original predictive approach that integrates an ensemble variable-selection strategy to reinforce the stability of the variable-selection process and multivariate modeling. Our predictive models explained up to 70% of total variability in Tac C0 per dose with a maximum of 44 gene variants (p-value <0.001 with a permutation test). These models included molecular networks of drug metabolism with oxidoreductase activities and the multidrug-resistant ABCC8 transporter, which was found in the most stringent model. Finally, we identified an intronic variant of the gene encoding SLC28A3, a drug transporter, as a key gene involved in Tac metabolism, and we confirmed it in an independent validation cohort.
Collapse
Affiliation(s)
- C Damon
- Hypercube Institute, Paris, France
| | - M Luck
- Hypercube Institute, Paris, France.,Paris Descartes University, Paris, France
| | - L Toullec
- Department of Clinical Chemistry, Georges Pompidou European Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
| | - I Etienne
- Department of Nephrology, Rouen University Hospital, Rouen, France
| | - M Buchler
- Department of Nephrology, Tours University Hospital, Tours, France
| | | | - G Choukroun
- Department of Nephrology, Amiens University Hospital, Amiens, France
| | - A Thierry
- Department of Nephrology, Poitiers University Hospital, Poitiers, France
| | - C Vigneau
- Department of Nephrology, Rennes University Hospital, Rennes, France
| | - B Moulin
- Department of Nephrology, Strasbourg University Hospital, Strasbourg, France
| | - A-E Heng
- Department of Nephrology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - J-F Subra
- Department of Nephrology, Angers University Hospital, Angers, France
| | - C Legendre
- Department of Nephrology, Necker Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
| | - A Monnot
- Hypercube Institute, Paris, France
| | | | | | - P Laurent-Puig
- Paris Descartes University, Paris, France.,Department of Clinical Chemistry, Georges Pompidou European Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.,Institut National pour la Santé et la Recherche Médicale (INSERM) U1147, Paris, France
| | - D Anglicheau
- Department of Nephrology, Necker Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
| | - P Beaune
- Paris Descartes University, Paris, France.,Department of Clinical Chemistry, Georges Pompidou European Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.,Institut National pour la Santé et la Recherche Médicale (INSERM) U1147, Paris, France
| | - M A Loriot
- Paris Descartes University, Paris, France.,Department of Clinical Chemistry, Georges Pompidou European Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.,Institut National pour la Santé et la Recherche Médicale (INSERM) U1147, Paris, France
| | - E Thervet
- Paris Descartes University, Paris, France.,Department of Nephrology, Georges Pompidou European Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
| | - N Pallet
- Paris Descartes University, Paris, France.,Department of Clinical Chemistry, Georges Pompidou European Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.,Institut National pour la Santé et la Recherche Médicale (INSERM) U1147, Paris, France.,Department of Nephrology, Georges Pompidou European Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
| |
Collapse
|
12
|
Perez AL, Nembhard M, Monnot A, Bator D, Madonick E, Gaffney SH. Child and adult exposure and health risk evaluation following the use of metal- and metalloid-containing costume cosmetics sold in the United States. Regul Toxicol Pharmacol 2017; 84:54-63. [DOI: 10.1016/j.yrtph.2016.12.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2016] [Revised: 12/07/2016] [Accepted: 12/08/2016] [Indexed: 01/27/2023]
|
13
|
Davidson TL, Monnot A, Neal AU, Martin AA, Horton JJ, Zheng W. The effects of a high-energy diet on hippocampal-dependent discrimination performance and blood-brain barrier integrity differ for diet-induced obese and diet-resistant rats. Physiol Behav 2012; 107:26-33. [PMID: 22634281 DOI: 10.1016/j.physbeh.2012.05.015] [Citation(s) in RCA: 143] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2012] [Revised: 03/13/2012] [Accepted: 05/14/2012] [Indexed: 02/01/2023]
Abstract
Rats that consume high-energy (HE) diets (i.e., diets high in saturated fats and sugar) show impaired hippocampal-dependent learning and memory (e.g., Kanoski and Davidson (2011) [1]). To further investigate this effect, we trained rats given restricted access to low-fat lab chow on hippocampal-dependent serial feature-negative (FN) and hippocampal-independent simple discrimination problems. When training was completed, Group Chow received ad libitum lab chow. The remaining rats received ad libitum HE diet. Performance on both discrimination problems was tested following 7, 14, 21 and 28 days of HE diet exposure. FN, but not simple discrimination, was abolished initially for all rats, and then re-emerged for Group Chow. For rats fed HE diet, those that weighed the least and had the lowest amount of body fat (HE-diet resistant (HE-DR) rats), performed like Group Chow on both discrimination problems. However, HE diet-induced obese (HE-DIO) rats (i.e., rats that weighed the most weight and had the most body fat) performed like Group Chow on the simple discrimination problem, but were impaired throughout testing on the FN problem. Subsequent assessment of blood-brain barrier (BBB) permeability revealed that concentrations of an exogenously administered dye were elevated in the hippocampus, but not in the striatum or prefrontal cortex for HE-DIO rats relative to the HE-DR and Chow groups. The results indicate that the adverse consequences of HE diet on hippocampal-dependent cognitive functioning are associated with detrimental effects on the BBB and that both of these outcomes vary with sensitivity to HE diet-induced increases in weight and adiposity.
Collapse
Affiliation(s)
- Terry L Davidson
- Department of Psychological Sciences, Purdue University, 703 Third Street, West Lafayette, IN 47907, USA.
| | | | | | | | | | | |
Collapse
|
14
|
Moutafis M, Hatahet Z, Castelain MH, Renaudin MH, Monnot A, Fischler M. Validation of a simple method assessing nitric oxide and nitrogen dioxide concentrations. Intensive Care Med 1995; 21:537-41. [PMID: 7560498 DOI: 10.1007/bf01706209] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Monitoring of nitric oxide (NO) and nitrogen dioxide (NO2) is a prerequisite for the clinical use of NO. Chemiluminescence, the reference method, cannot be used as a routine in clinical practice in view of its cost and other restraints. This study was performed to evaluate a device using an electrochemical method (Polytrons NO and NO2, Dräger). Forty-nine simultaneous measurements of NO and various oxides of nitrogen (NOx) concentrations by the two apparatus were performed. NO measurements by means of these two methods are very well correlated (r = 0.96; p < 10(-5)). The mean difference according to the method of Bland and Altman was 2.8 +/- 1.7 ppm, with the limits of agreement at -0.6 and +6.2 ppm (confidence interval of 95%). There was also a good correlation between measurements of NO2 obtained via Polytrons and NOx via chemiluminescence (r = 0.84; p < 10(-5)). However, NO2 measurements obtained via Polytrons may be insufficient to exclude potential toxicity of NO2 due to the inability to detect measurements in the ppb-range. This study demonstrates that devices designed for industrial purposes (Polytrons NO and NO2, Dräger) can be used for clinical purposes.
Collapse
Affiliation(s)
- M Moutafis
- Service d'Anesthésie, CMC Foch, Suresnes, France
| | | | | | | | | | | |
Collapse
|
15
|
Abstract
A new physical model simulating the pharmacokinetics of volatile anaesthetics is presented. It consists in a ventilator connected to a water manometer. Gas is removed from the gaseous part of this manometer with a constant rate pump. This gas flow is directed thereafter into three capacitances with valves and pumps: one capacitance only contains air, representing the lungs, and the other two olive oil, representing the visceral and muscle compartments. Halothane, enflurane and isoflurane (1 vol%) were administered to this model with different values of cardiac output and alveolar ventilation. There was good concordance between the values of FA/FI that were measured in this model and those calculated by computer simulation. No correction factor was required. Such a physical model may therefore be used to test new techniques of administration of volatile agents.
Collapse
Affiliation(s)
- M H Renaudin
- L'Air Liquide, Centre de Recherche Claude-Delorme, Jouy-en-Josas
| | | | | | | |
Collapse
|
16
|
Monnot A, Inglis. Observations sur la cataracte. Ann Med (Edinb) 1802; 2:416-427. [PMID: 30299720 PMCID: PMC5110700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- A. Monnot
- professeur d'Anatomie et d'Accouchement à Besançon
| | | |
Collapse
|